Medicus Pharma Ltd. filed a Form 425 on November 6, 2026, disclosing third-quarter 2026 financial results, a co-development and license agreement with Pfizer for CD228V, a non-binding letter of intent for a proposed SkinJect SPAC business combination at approximately $135 million pre-money enterprise valuation, and the regaining of Nasdaq minimum bid price compliance following a 50-to-1 share consolidation.

Key Highlights

  • CD228V designated principal priority: Medicus entered a co-development and licensing agreement with Pfizer on September 2, 2026, granting an exclusive worldwide license for CD228V, a clinical-stage antibody-drug conjugate targeting CD228, with Pfizer providing $2.0 million in development funding.
  • SkinJect SPAC LOI announced: On November 4, 2026, Medicus announced a non-binding letter of intent with an undisclosed SPAC contemplating an approximate $135 million pre-money enterprise valuation for SkinJect, Inc.
  • Net loss of $15.2 million in Q3 2026: The company reported a net loss of $15.2 million for the quarter ended September 30, 2026, compared with $16.0 million in Q3 2025.
  • Cash position: Cash and cash equivalents stood at $5.0 million as of September 30, 2026, down from $8.7 million as of December 31, 2025; total cash, cash equivalents, and restricted cash were $13.1 million.
  • Nasdaq compliance regained: Following a 50-to-1 share consolidation effective October 12, 2026, Medicus received written notice from Nasdaq on October 23, 2026, confirming compliance with the minimum bid price requirement.
  • Teverelix protocol submitted: On September 29, 2026, Medicus submitted a proposed seamless Phase 2b/3 registration-intent protocol to the FDA for Teverelix for patients at increased cardiovascular risk, with an expected total enrollment of approximately 608 patients.
  • SEPA terminated: Medicus and YA II PN, Ltd. mutually agreed to terminate the standby equity purchase agreement effective September 11, 2026, with no borrowings, advance notices, or shares outstanding at termination.

Medicus Pharma's Q3 2026 Portfolio Repositioning and Financial Results

According to the filing, Medicus Pharma Ltd. (NASDAQ:MDCX) reported total operating expenses (loss from operations) of $14.5 million for Q3 2026, compared with $15.4 million in Q3 2025. General and administrative expenses declined to $2.5 million from $5.0 million in the prior-year period, while research and development expenses increased to $2.0 million from $1.7 million. Net loss per share was $11.64, compared with $56.18 in Q3 2025; the filing notes that share and per share amounts for all periods have been retroactively adjusted to reflect the 50-to-1 share consolidation effective October 12, 2026.

The filing describes CD228V as a second-generation CD228-targeted antibody-drug conjugate utilizing Pfizer's established vedotin linker-payload platform. Under the co-development framework, Medicus controls program execution. Pfizer retains the right, without obligation, to elect to fund all or part of development beginning with the first pivotal trial, subject to a further definitive agreement. Medicus stated its initial clinical focus will be relapsed, refractory, or immunotherapy-resistant melanoma, supported by an existing U.S. investigational new drug application and a first-in-human Phase 1 clinical study.

Regarding SkinJect, the filing states the FDA issued a "Study May Proceed" letter for SKNJCT-005, the planned registrational Phase 2b study in Gorlin syndrome, in July. The clinical study report for the completed SKNJCT-003 Phase 2 study was finalized in September. The filing also notes that the FDA has held review of Orphan Drug Designation and Rare Pediatric Disease Designation applications in abeyance pending receipt of additional information. For Teverelix, Medicus stated it intends to seek an out-license or strategic partnership rather than independently fund the proposed study, and that there can be no assurance that the company will successfully enter into any such transaction.

What Was Disclosed

Medicus Pharma disclosed Q3 2026 financial results, a Pfizer co-development agreement for CD228V with $2.0 million in Pfizer funding, a non-binding SPAC LOI for SkinJect at approximately $135 million, Teverelix FDA protocol submission, SEPA termination, and restored Nasdaq bid-price compliance.